vs
Civeo Corp（CVEO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Civeo Corp的1.4倍（$219.9M vs $161.6M），Orthofix Medical Inc.净利率更高（-1.0% vs -4.0%，领先3.0%），Civeo Corp同比增速更快（7.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $14.5M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -1.4%）
希维欧公司（Civeo Corporation）是一家美国住宿服务跨国企业，从石油国家国际公司（Oil States International）拆分而来，目前是在纽约证券交易所挂牌上市的公众公司，主要为能源等行业项目提供人员住宿配套服务解决方案。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CVEO vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$161.6M
营收增速更快
CVEO
高出5.1%
2.0%
净利率更高
OFIX
高出3.0%
-4.0%
自由现金流更多
OFIX
多$2.4M
$14.5M
两年增速更快
OFIX
近两年复合增速
-1.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $161.6M | $219.9M |
| 净利润 | $-6.5M | $-2.2M |
| 毛利率 | 22.7% | 71.1% |
| 营业利润率 | -0.1% | 0.2% |
| 净利率 | -4.0% | -1.0% |
| 营收同比 | 7.1% | 2.0% |
| 净利润同比 | 58.1% | 92.4% |
| 每股收益（稀释后） | $-0.58 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVEOOFIX
| Q4 25 | $161.6M | $219.9M | ||
| Q3 25 | $170.5M | $205.6M | ||
| Q2 25 | $162.7M | $203.1M | ||
| Q1 25 | $144.0M | $193.6M | ||
| Q4 24 | $151.0M | $215.7M | ||
| Q3 24 | $176.3M | $196.6M | ||
| Q2 24 | $188.7M | $198.6M | ||
| Q1 24 | $166.1M | $188.6M |
净利润CVEOOFIX
| Q4 25 | $-6.5M | $-2.2M | ||
| Q3 25 | $-455.0K | $-22.8M | ||
| Q2 25 | $-3.3M | $-14.1M | ||
| Q1 25 | $-9.8M | $-53.1M | ||
| Q4 24 | $-15.4M | $-29.1M | ||
| Q3 24 | $-5.1M | $-27.4M | ||
| Q2 24 | $8.2M | $-33.4M | ||
| Q1 24 | $-5.1M | $-36.0M |
毛利率CVEOOFIX
| Q4 25 | 22.7% | 71.1% | ||
| Q3 25 | 25.7% | 72.2% | ||
| Q2 25 | 25.3% | 68.7% | ||
| Q1 25 | 20.4% | 62.8% | ||
| Q4 24 | 18.6% | 69.0% | ||
| Q3 24 | 21.4% | 68.7% | ||
| Q2 24 | 25.4% | 67.8% | ||
| Q1 24 | 21.5% | 67.5% |
营业利润率CVEOOFIX
| Q4 25 | -0.1% | 0.2% | ||
| Q3 25 | 4.1% | -8.3% | ||
| Q2 25 | 1.7% | -7.9% | ||
| Q1 25 | -3.8% | -25.2% | ||
| Q4 24 | -6.7% | -5.3% | ||
| Q3 24 | 0.0% | -9.6% | ||
| Q2 24 | 6.9% | -12.5% | ||
| Q1 24 | -1.1% | -15.6% |
净利率CVEOOFIX
| Q4 25 | -4.0% | -1.0% | ||
| Q3 25 | -0.3% | -11.1% | ||
| Q2 25 | -2.0% | -6.9% | ||
| Q1 25 | -6.8% | -27.4% | ||
| Q4 24 | -10.2% | -13.5% | ||
| Q3 24 | -2.9% | -13.9% | ||
| Q2 24 | 4.4% | -16.8% | ||
| Q1 24 | -3.1% | -19.1% |
每股收益（稀释后）CVEOOFIX
| Q4 25 | $-0.58 | $-0.05 | ||
| Q3 25 | $-0.04 | $-0.57 | ||
| Q2 25 | $-0.25 | $-0.36 | ||
| Q1 25 | $-0.72 | $-1.35 | ||
| Q4 24 | $-1.04 | $-0.76 | ||
| Q3 24 | $-0.36 | $-0.71 | ||
| Q2 24 | $0.56 | $-0.88 | ||
| Q1 24 | $-0.35 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.4M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $174.4M | $450.0M |
| 总资产 | $477.4M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVEOOFIX
| Q4 25 | $14.4M | $82.0M | ||
| Q3 25 | $12.0M | $62.9M | ||
| Q2 25 | $14.6M | $65.6M | ||
| Q1 25 | $28.4M | $58.0M | ||
| Q4 24 | $5.2M | $83.2M | ||
| Q3 24 | $17.9M | $30.1M | ||
| Q2 24 | $7.4M | $26.4M | ||
| Q1 24 | $16.8M | $27.0M |
总债务CVEOOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $43.3M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益CVEOOFIX
| Q4 25 | $174.4M | $450.0M | ||
| Q3 25 | $182.5M | $442.5M | ||
| Q2 25 | $209.4M | $458.3M | ||
| Q1 25 | $220.7M | $458.3M | ||
| Q4 24 | $236.4M | $503.1M | ||
| Q3 24 | $282.2M | $525.9M | ||
| Q2 24 | $297.4M | $546.0M | ||
| Q1 24 | $297.4M | $570.3M |
总资产CVEOOFIX
| Q4 25 | $477.4M | $850.6M | ||
| Q3 25 | $491.1M | $832.6M | ||
| Q2 25 | $508.8M | $837.2M | ||
| Q1 25 | $423.8M | $823.1M | ||
| Q4 24 | $405.1M | $893.3M | ||
| Q3 24 | $477.6M | $867.9M | ||
| Q2 24 | $483.2M | $882.0M | ||
| Q1 24 | $513.1M | $906.0M |
负债/权益比CVEOOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.18× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $14.5M | $16.8M |
| 自由现金流率自由现金流/营收 | 8.9% | 7.6% |
| 资本支出强度资本支出/营收 | 3.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CVEOOFIX
| Q4 25 | $19.3M | $27.7M | ||
| Q3 25 | $13.8M | $12.4M | ||
| Q2 25 | $-2.3M | $11.6M | ||
| Q1 25 | $-8.4M | $-18.4M | ||
| Q4 24 | $9.5M | $23.7M | ||
| Q3 24 | $35.7M | $11.7M | ||
| Q2 24 | $32.4M | $9.0M | ||
| Q1 24 | $6.0M | $-18.6M |
自由现金流CVEOOFIX
| Q4 25 | $14.5M | $16.8M | ||
| Q3 25 | $8.2M | $2.5M | ||
| Q2 25 | $-6.8M | $4.5M | ||
| Q1 25 | $-13.7M | $-25.1M | ||
| Q4 24 | $1.8M | $15.2M | ||
| Q3 24 | $28.2M | $6.3M | ||
| Q2 24 | $27.0M | $-360.0K | ||
| Q1 24 | $372.0K | $-29.1M |
自由现金流率CVEOOFIX
| Q4 25 | 8.9% | 7.6% | ||
| Q3 25 | 4.8% | 1.2% | ||
| Q2 25 | -4.2% | 2.2% | ||
| Q1 25 | -9.5% | -13.0% | ||
| Q4 24 | 1.2% | 7.0% | ||
| Q3 24 | 16.0% | 3.2% | ||
| Q2 24 | 14.3% | -0.2% | ||
| Q1 24 | 0.2% | -15.4% |
资本支出强度CVEOOFIX
| Q4 25 | 3.0% | 4.9% | ||
| Q3 25 | 3.3% | 4.8% | ||
| Q2 25 | 2.8% | 3.5% | ||
| Q1 25 | 3.7% | 3.5% | ||
| Q4 24 | 5.1% | 4.0% | ||
| Q3 24 | 4.2% | 2.7% | ||
| Q2 24 | 2.8% | 4.7% | ||
| Q1 24 | 3.4% | 5.6% |
现金转化率CVEOOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVEO
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
